Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Pharmacol Res. 2019 Jan 3;141:249–263. doi: 10.1016/j.phrs.2019.01.006

FIGURE 6: Pharmacological inhibition of FoxO1/3a or stromelysin1 has beneficial effects on LPS- induced lung injury and edema.

FIGURE 6:

(A) Bar graph showing increased stromelysin1 activity in mouse BALF upon LPS injury and its significant inhibition upon FoxO1/3a knock down or co-treatment with stromelysin1 inhibitor (n=6). (B) Bar graph showing increased stromelysin1 activity in mouse lung tissues upon LPS injury and its significant inhibition upon FoxO1/3a knock down or co-treatment with inhibitor stromelysin1 (n=6). (C) Bar graph showing significantly increased myeloperoxidase (MPO) activity in mouse lungs after LPS injury and a significant inhibition with FoxO1/3a and stromelysin1 inhibition (n=6). (D-E) Representative Western blot images and band densitometry analysis showing increased stromelysin1 expression in lung tissue lysates with LPS injury and its significant reversal upon FoxO1/3a knock down or co-treatment with an inhibitor of stromelysin1 (n=6). (F-G) Representative Western blot images and band densitometry analysis showing decreased claudin5 expression in lung tissue lysates with LPS injury and its significant reversal upon FoxO1/3a knockdown or co-treatment with an inhibitor of stromelysin1 (n=6). (H) Stromelysin1 (MMP3) regulates ARDS genes and pathology in humans and rodents as identified from genome-wide association studies using ingenuity pathway analysis. * (p<0.05); # (p<0.01); MPO: Myeloperoxidase, One-way ANOVA-Ordinary for more than two groups (GraphPad Prism 6.01).